id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-355971-99mhacqa	Gougis, Paul	Anticancer drugs and COVID-19 antiviral treatments in cancer patients: what can we safely use?	2020-06-10		.txt	text/plain	761	63	38	title: Anticancer drugs and COVID-19 antiviral treatments in cancer patients: what can we safely use? • More safety data is needed to treat COVID-19 symptomatic patients with anticancer drugs known to increase infections. • A ready-to-use table synthetize these pharmacokinetic and pharmacodynamic interactions between antiviral and anticancer drugs. 1 In any of these settings, clinical trials and incoming standard of care could lead to the prescription of antiviral drugs concomitant to non-immunosuppressive anticancer treatments. Favipiravir, an anti-EBOV drug, also a candidate for the COVID-19 treatment, is an inhibitor of CYP2C8, 3 and therefore may increase anticancer drug metabolized through this pathway, such as dabrafenib and enzalutamide. The table (part B) summarizes pharmacokinetic and pharmacodynamics interactions between some currently tested drugs against COVID-19 and anticancer drugs. Orange boxes are for anticancer drugs prolonging QT without known Torsade-de-Pointes risk and moderate risk for renal and liver toxicities.	./cache/cord-355971-99mhacqa.txt	./txt/cord-355971-99mhacqa.txt